Citron DM - Search Results

1

Impact of an intervention to control Clostridium difficile infection on hospital- and community-onset disease; an interrupted time series analysis.

Price J, Cheek E, Lippett S, Cubbon M, Gerding DN, Sambol SP, Citron DM, Llewelyn M. Price J, et al. Among authors: citron dm. Clin Microbiol Infect. 2010 Aug;16(8):1297-302. doi: 10.1111/j.1469-0691.2009.03077.x. Epub 2009 Oct 14. Clin Microbiol Infect. 2010. PMID: 19832710 Free article.

2

Predictors of death after Clostridium difficile infection: a report on 128 strain-typed cases from a teaching hospital in the United Kingdom.

Wilson V, Cheek L, Satta G, Walker-Bone K, Cubbon M, Citron D, Gerding DN, Llewelyn MJ. Wilson V, et al. Clin Infect Dis. 2010 Jun 15;50(12):e77-81. doi: 10.1086/653012. Clin Infect Dis. 2010. PMID: 20450417

3

Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin.

Figueroa I, Johnson S, Sambol SP, Goldstein EJ, Citron DM, Gerding DN. Figueroa I, et al. Among authors: citron dm. Clin Infect Dis. 2012 Aug;55 Suppl 2(Suppl 2):S104-9. doi: 10.1093/cid/cis357. Clin Infect Dis. 2012. PMID: 22752857 Free PMC article. Clinical Trial.

4

Bezlotoxumab for the Prevention of Recurrent Clostridioides difficile Infection: 12-Month Observational Data From the Randomized Phase III Trial, MODIFY II.

Goldstein EJC, Citron DM, Gerding DN, Wilcox MH, Gabryelski L, Pedley A, Zeng Z, Dorr MB. Goldstein EJC, et al. Among authors: citron dm. Clin Infect Dis. 2020 Aug 14;71(4):1102-1105. doi: 10.1093/cid/ciz1151. Clin Infect Dis. 2020. PMID: 31883370 Free article. Clinical Trial.

5

Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes.

Johnson S, Citron DM, Gerding DN, Wilcox MH, Goldstein EJC, Sambol SP, Best EL, Eves K, Jensen E, Dorr MB. Johnson S, et al. Among authors: citron dm. Clin Infect Dis. 2021 Nov 2;73(9):e2616-e2624. doi: 10.1093/cid/ciaa1035. Clin Infect Dis. 2021. PMID: 32735653 Clinical Trial.

6

Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.

Citron DM, Babakhani F, Goldstein EJ, Nagaro K, Sambol S, Sears P, Shue YK, Gerding DN. Citron DM, et al. Anaerobe. 2009 Dec;15(6):234-6. doi: 10.1016/j.anaerobe.2009.09.005. Epub 2009 Sep 12. Anaerobe. 2009. PMID: 19755166 Clinical Trial.

7

Comparative susceptibilities to fidaxomicin (OPT-80) of isolates collected at baseline, recurrence, and failure from patients in two phase III trials of fidaxomicin against Clostridium difficile infection.

Goldstein EJ, Citron DM, Sears P, Babakhani F, Sambol SP, Gerding DN. Goldstein EJ, et al. Among authors: citron dm. Antimicrob Agents Chemother. 2011 Nov;55(11):5194-9. doi: 10.1128/AAC.00625-11. Epub 2011 Aug 15. Antimicrob Agents Chemother. 2011. PMID: 21844318 Free PMC article. Clinical Trial.

8

Molecular epidemiology of Clostridioides (Clostridium) difficile strains recovered from clinical trials in the US, Canada and Europe from 2006-2009 to 2012-2015.

Cheknis A, Johnson S, Chesnel L, Petrella L, Sambol S, Dale SE, Nary J, Sears P, Citron DM, Goldstein EJC, Gerding DN. Cheknis A, et al. Among authors: citron dm. Anaerobe. 2018 Oct;53:38-42. doi: 10.1016/j.anaerobe.2018.05.009. Epub 2018 May 26. Anaerobe. 2018. PMID: 29886050

9

Effects of control interventions on Clostridium difficile infection in England: an observational study.

Dingle KE, Didelot X, Quan TP, Eyre DW, Stoesser N, Golubchik T, Harding RM, Wilson DJ, Griffiths D, Vaughan A, Finney JM, Wyllie DH, Oakley SJ, Fawley WN, Freeman J, Morris K, Martin J, Howard P, Gorbach S, Goldstein EJC, Citron DM, Hopkins S, Hope R, Johnson AP, Wilcox MH, Peto TEA, Walker AS, Crook DW; Modernising Medical Microbiology Informatics Group. Dingle KE, et al. Among authors: citron dm. Lancet Infect Dis. 2017 Apr;17(4):411-421. doi: 10.1016/S1473-3099(16)30514-X. Epub 2017 Jan 25. Lancet Infect Dis. 2017. PMID: 28130063 Free PMC article.

10

Characterization of Clostridioides difficile isolates recovered from two Phase 3 surotomycin treatment trials by restriction endonuclease analysis, PCR ribotyping and antimicrobial susceptibilities.

Cheknis A, Devaris D, Chesnel L, Dale SE, Nary J, Sambol SP, Citron DM, Goering RV, Johnson S. Cheknis A, et al. Among authors: citron dm. J Antimicrob Chemother. 2020 Nov 1;75(11):3120-3125. doi: 10.1093/jac/dkaa297. J Antimicrob Chemother. 2020. PMID: 32747931

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

240 results

Search Page

Filters